IBRX
ImmunityBio, Inc. · Healthcare
7.08
3.01%(-0.22)
Prev. Close6.99
1.27%(-0.09)
Pre-marketLast Updated: — ET
52W L: $1.8352W H: $12.43
$6.98
CHG-1.39 (-16.61%)
H$9.60
L$6.52
VOL538M
IBRX (1h)
ImmunityBio, Inc. · Healthcare
NEW YORK, April 7, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So What: If you purchased ImmunityBio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
It sent the company a warning letter about a TV ad and a podcast episode about Anktiva. ImmunityBio sounded a contrite note in response.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 6, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
SAN FRANCISCO, April 06, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by its executive chairman and Chief Scientific and Medical Officer (Dr.
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced it has submitted a comprehensive response to the U.S. Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP) regarding issues raised on March 13, 2026 related to a television advertisement and a podcast. The company addressed the concerns related to the podcast and informed OPDP that the television advertisement was never aired. The response.
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”), have until May 26, 2026 to seek appointment as lead plaintiff of the ImmunityBio class action lawsuit. Captioned Douglas v.
SOON-SHIONG PATRICK
director, 10 percent owner, officer: See remarks
4,606,596 SH @ $5.43
2026-03-31
SOON-SHIONG PATRICK
director, 10 percent owner, officer: See remarks
0 SH @ $5.43
2026-03-31
Simon Barry J.
director
75,000 SH @ $12.01
2026-02-24
Selecky Christobel
director
25,000 SH @ $2.98
2026-02-23
Selecky Christobel
director
25,000 SH @ $2.98
2026-02-23
Selecky Christobel
director
25,000 SH @ $10.00
2026-02-23
Sachs David C.
officer: Chief Financial Officer
40,650 SH @ $0.00
2026-02-22
Sachs David C.
officer: Chief Financial Officer
20,682 SH @ $8.70
2026-02-22